We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A small randomized trial in Argentina has found that the early use of convalescent plasma in COVID-19-infected adults helped to reduce progression to severe disease. Read More
German vaccine developer CureVac has secured a deal with Bayer to help gain regulatory approvals worldwide for its messenger RNA-based COVID-19 vaccine candidate, CVnCoV. Read More
Scientists are closely monitoring the potential impact of mutations of the SARS-CoV-2 virus on the effectiveness of COVID-19 vaccines, but for the moment the new strains don’t appear able to completely evade their protective effect. Read More
The European Commission granted conditional marketing authorization for Moderna’s highly effective COVID-19 vaccine Wednesday, adding a second messenger RNA-based vaccine to its arsenal against the pandemic. Read More
The U.S. government is moving ahead of schedule on a vaccine partnership with pharmacies across the country to speed up inoculations with the Pfizer/BioNTech and Moderna vaccines and it will start the program this week, HHS Secretary Alex Azar announced yesterday. Read More
Healthcare providers that used the test and suspect a recent inaccurate result should consider retesting patients with a different COVID-19 test, the agency said. Read More
South Africa received the discounted price because it is considered a developing nation and because the vaccine is being evaluated in a phase 3 trial in the country. Read More
Emergex and Brazil’s Institute of Technology on Immunobiologicals (Bio-Manguinhos) have agreed to work together on “certain immunotherapeutic programs” including a COVID-19 vaccine. Read More
The FDA made the right call in strongly advising against using a half-dose regimen of Moderna’s COVID-19 vaccine to stretch supply and vaccinate more Americans, members of the agency’s vaccine advisory panel told FDAnews. Read More